Flattening the Curve of COVID-19 Vaccine Rejection-An International Overview

If globally implemented, a safe coronavirus disease 2019 (COVID-19) vaccination program will have broad clinical and socioeconomic benefits. However, individuals who anticipate that the coronavirus vaccine will bring life back to normality may be disappointed, due to the emerging antivaccination att...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2021-01, Vol.9 (1), p.44
Main Authors: Feleszko, Wojciech, Lewulis, Piotr, Czarnecki, Adam, Waszkiewicz, Paweł
Format: Article
Language:English
Subjects:
Adults
Attitudes
Coronaviridae
Coronaviruses
COVID-19
COVID-19 vaccines
Data collection
Herd immunity
Language policy
Medical research
Pandemics
Polls & surveys
Reluctance
Search strategies
Severe acute respiratory syndrome coronavirus 2
Software
Vaccination
vaccine hesitancy
Vaccines
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:If globally implemented, a safe coronavirus disease 2019 (COVID-19) vaccination program will have broad clinical and socioeconomic benefits. However, individuals who anticipate that the coronavirus vaccine will bring life back to normality may be disappointed, due to the emerging antivaccination attitude within the general population. We surveyed a sample of adult Polish citizens ( = 1066), and compared it with the data on international COVID-19 vaccine reluctance. In 20 national surveys, the vaccine averseness for the anticipated COVID-19 vaccine varied from meager (2-6% China) to very high (43%, Czech Republic, and 44%, Turkey) and in most countries was much higher than regular vaccination reluctance, which varies between 3% (Egypt) and 55% (Russia). These results suggest that a 67% herd immunity may be possible only if mandatory preventive vaccination programs start early and are combined with coordinated education efforts supported by legislative power and social campaigns.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines9010044